S-adenosylmethionine therapy in rheumatic and related autoimmune diseases
DOI:
https://doi.org/10.21638/10.21638/spbu11.2023.401Abstract
S-adenosylmethionine has been used to treat neuropsychiatric diseases, including those accompanied with depression. These entities often are comorbid with rheumatic and thyroid pathology, and in the COVID-19 pandemic and post-pandemic periods, there was a growing number of such cases. That’s why the article evaluates the experience and perspectives of S-adenosylmethionine therapy in osteoarthritis and a few rheumatic and comorbid thyroid diseases (fibromyalgia, systemic sclerosis, gout and autoimmune thyroiditis). PubMed/MEDLINE, EMBASE, elibrary.ru and Scielo databases were searched for targeted topic between 1966 and 2023. 15 articles were depicted to fulfill the inclusion criteria, 13 in Latin and 2 in Cyrillic scripts, including 1,499 patients (1,383 in osteoarthritis and 116 in other rheumatic diseases). The dosage varied from 200 mg to 1,200 mg/day. The follow-up ranged from 3 weeks to 24 months. Almost all studies (13/15) showed at least one benefit after S-adenosylmethionine therapy supplementation, including 2 papers documented positive effect in vitro achieved upon the cells taken from patients. Most side effects were mild, one study showed borderline moderate/severe adverse effects. Only preclinical/experimental studies of S-adenosylmethionine therapy effects on thyroid regulation were revealed. S-adenosylmethionine is a promising and safe element of complex therapy for some rheumatic diseases.
Keywords:
S-adenosylmethionine, SAMe, methylation, rheumatic diseases, rheumatoid arthritis, systemic sclerosis, osteoarthritis, fibromyalgia, thyroid gland
Downloads
Download data is not yet available.
References
References
Bottiglieri T., Laundy M., Martin R., Carney M. W., Nissenbaum H., Toone B. K., Johnson A. L., Reynolds E. H. S-adenosylmethionine influences monoamine metabolism. The Lancet, 1984, vol. 324, p. 224.
Surtees R., Leonard J., Austin S. Association of demyelination with deficiency of cerebrospinal-fluid s-adenosylmethionine in inborn errors of methyl-transfer pathway. Lancet, 1991, vol. 338, pp. 1550–1554.
Bottiglieri T., Godfrey P., Flynn T., Carney M. W., Toone B. K., Reynolds E. H. Cerebrospinal fluid s-adenosylmethionine in depression and dementia: Effects of treatment with parenteral and oral s-adenosylmethionine. J. Neurol. Neurosurg. Psychiatry, 1990, vol. 53, pp. 1096–1098.
Hardy M. L., Coulter I. D., Favreau J. T., Morton S. C., Venuturupalli S. R., Chiapelli F., Rossi F., Orshansky G., Jungvig L. K., Roth E. A., Suttorp M. J., Shekelle P. S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease. Evid. Rep. Technol. Assess. (Summ.), 2003, vol. 64, pp. 1–3.
Baranovskij A. Yu., Rajhel’son K. L., Marchenko N. V. The use of s-adenosylmethionine (heptral®) in the treatment of patients with non-alcoholic steatohepatitis. Klinicheskie perspektivy gastroenterologii,gepatologii, 2010, vol. 1, pp. 3–10. (In Russian)
Lukivskaya O. Ya., Belonovskaya E. B., Naruta E. E., Kuz’mickaya I. A., Kirko S. N., Buko V. U. S-adenosylmethionine for the correction of experimental hepatic encephalopathy. Hepatology and gastroenterology,2019, vol. 3, no. 2, pp. 166–171. (In Russian)
di Padova C. S-adenosylmethionine in the treatment of osteoarthritis. Review of the clinical studies.Am. J. Med., 1987, vol. 83, pp. 60–65.
Ouyang Y., Wu Q., Li J., Sun S., Sun S. S-adenosylmethionine: A metabolite critical to the regulation of autophagy. Cell Prolif., 2020, vol. 53, no. 11, e12891. https://doi.org/10.1111/cpr.12891
Pascale R. M., Simile M. M., Calvisi D. F., Feo C. F., Feo F. S-Adenosylmethionine: From the Discovery of Its Inhibition of Tumorigenesis to Its Use as a Therapeutic Agent. Cells,2022, vol. 11, no. 3, p. 409. https://doi.org/10.3390/cells11030409
Kryukov E. V., Ivanov A. V., Karpov V. O., Aleksandrin V. V., Dygai A. M., Kruglova M. P., Kostiuchenko G. I., Kazakov S. P., Kubatiev A. A. Plasma S-Adenosylmethionine Is Associated with Lung Injury in COVID-19. Dis. Markers, 2021, vol. 2021, e7686374.
Kim J., Lee E. Y., Koh E. M., Cha H. S., Yoo B., Lee C. K., Lee Y. J., Ryu H., Lee K. H., Song Y. W. Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patients. Clin. Ther., 2009, vol. 31, no. 12, pp. 2860–2872.
Najm W. I., Reinsch S., Hoehler F., Tobis J. S., Harvey P. W. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495]. BMC Musculoskelet Disord., 2004, vol. 5, p. 6.
Caruso I., Pietrogrande V. Italian double-blind multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint disease. Am. J. Med., 1987, vol. 83, no. 5ª,pp. 66–71.
Müller-Fassbender H. Double-blind clinical trial of S-adenosylmethionine versus ibuprofen in treatment of osteoarthritis. Am. J. Med., 1987, vol. 83, no. 5ª, pp. 81–83.
König B. A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis. Am. J. Med., 1987, vol. 83, no. 5ª, pp. 89–94.
Maccagno A., Di Giorgio E. E., Caston O. L., Sagasta C. L. Double-blind controlled clinical trial of oral S-adenosylmethionine versus piroxicam in knee osteoarthritis. Am. J. Med., 1987, vol. 83, no. 5ª,pp. 72–77.
Vetter G. Double-blind comparative clinical trial with S-adenosylmethionine and indomethacin in the treatment of osteoarthritis. Am. J. Med., 1987, vol. 83, no. 5ª, pp. 78–80.
Montrone F., Fumagalli M., Sarzi Puttini P., Boccassini L., Santandrea S., Volpato R., Locati M., Caruso I. Double-blind study of S-adenosyl-methionine versus placebo in hip and knee arthrosis. Clin. Rheumatol., 1985, vol. 4, no. 4, pp. 484–485.
Glorioso S., Todesco S., Mazzi A., Marcolongo R., Giordano M., Colombo B., Cherie-Ligniere G., Mattara L., Leardini G., Passeri M. Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis. Int. J. Clin. Pharmacol. Res., 1985, vol. 5, no. 1, pp. 39–49.
Page M. J., McKenzie J. E., Bossuyt P. M., Boutron I., Hoffmann T. C., Mulrow C. D., Shamseer L., Tetzlaff J. M., Akl E. A., Brennan S. E., Chou R., Glanville J., Grimshaw J. M., Hróbjartsson A., Lalu M. M., Li T., Loder E. W., Mayo-Wilson E., McDonald S., McGuinness L. A., Stewart L. A., Thomas J., Tricco A. C., Welch V. A., Whiting P., Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 2021, vol. 372, p. 71.
Volkmann H., Nørregaard J., Jacobsen S., Danneskiold-Samsøe B., Knoke G., Nehrdich D. Doubleblind, placebo-controlled cross-over study of intravenous S-adenosyl-L-methionine in patients with fibromyalgia. Scand. J. Rheumatol., 1997, vol. 26, no. 3, pp. 206–211.
Jacobsen S., Danneskiold-Samsøe B., Andersen R. B. Oral S-adenosylmethionine in primary fibromyalgia.Double-blind clinical evaluation. Scand. J. Rheumatol., 1991, vol. 20, no. 4, pp. 294–302.
Tavoni A., Vitali C., Bombardieri S., Pasero G. Evaluation of S-adenosylmethionine in primary fibromyalgia.A double-blind crossover study. Am. J. Med., 1987, vol. 83, no. 5ª, pp. 107–110.
Chen B. C., Balasubramaniam S., McGown I. N., O’Neill J. P., Chng G. S., Keng W. T., Ngu L. H., Duley J. A. Treatment of Lesch-Nyhan disease with S-adenosylmethionine: Experience with five young Malaysians, including a girl. Brain Dev., 2014, vol. 36, no. 7, pp. 593–600.
Oriente P., Scarpa R., Biondi C., Riccio A., Farinaro C., Del Puente A. Progressive systemic sclerosis and S-adenosylmethionine. Clin. Rheumatol., 1985, vol. 4, no. 3, pp. 360–361.
Shnajder M. A., Kalinovskaya N. Yu. Pleiotropic effect of DNA methylation modulators on synovial fibroblasts of patients with rheumatoid arthritis in vitro. Russian Journal of Immunologу, 2019, vol. 13,no. 2-1 (22), pp. 663–635. (In Russian)
Shnajder M. A., Shirinskij V. S., Kalinovskaya N. Yu., Shirinskij I. V. Effect of DNA methylation modulators on osteoprotegerin production by rheumatoid fibroblast-like synoviocytes in vitro, their migration and invasion. Bulletin of Siberian Medicine, 2019, vol. 18, no. 3, pp. 116–124. (In Russian)
Shishiba Y., Ozawa Y. The effect of S-adenosyl methionine on the TSH receptor function in human thyroid tissue: increase in binding of TSH and decrease in adenylate cyclase coupling. Endocrinol. Jpn., 1982, vol. 29, no. 5, pp. 589–592. https://doi.org/10.1507/endocrj1954.29.589
Keating J. N., Kusano G., Stokstad E. L. Effect of thiouracil in modifying folate function in severe vitamin B12 deficiency. Arch. Biochem. Biophys., 1988, vol. 267, no. 1, pp. 119–124. https://doi.org/10.1016/0003-9861(88)90015-x
Friedel H. A., Goa K. L., Benfield P. S-adenosyl-L-methionine. A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders concerning its physiological role in cell metabolism. Drugs, 1989, vol. 38, pp. 389–416.
Bottiglieri T. S-Adenosyl-L-methionine (SAMe): From the bench to the bedside- molecular basis of a pleiotropic molecule. Am. J. Clin. Nutr., 2002, vol. 76, 1151S-7S.
Harmand M. F., Vilamitjana J., Maloche E., Duphil R., Ducassou D. Effects of S-adenosylmethionine on human articular chondrocyte differentiation. An in vitro study. Am. J. Med., 1987, vol. 83, pp. 48–54.
Barcelo H. A., Wiemeyer J. C., Sagasta C. L., Macias M., Barreira J. C. Effect of S-adenosylmethionine on experimental osteoarthritis in rabbits. Am. J. Med., 1987, vol. 83, pp. 55–59.
Gutierrez S., Palacios I., Sanchez-Pernaute O., Gutierrez S., Palacios I., Sánchez-Pernaute O., Hernández P., Moreno J., Egido J., Herrero-Beaumont G. SAMe restores the changes in the proliferation and the synthesis of fibronectin and proteoglycans induced by tumor necrosis factor-alpha on cultured rabbit synovial cells. Br. J. Rheumatol., 1997, vol. 36, pp. 27–31.
Colombatto S., Fasulo L., Grillo M. A. Polyamines in rat liver during experimental inflammation.Agents Actions, 1988, vol. 24, no. 3–4, pp. 326–330.
Soeken K. L., Lee W. L., Bausell R. B., Agelli M., Berman B. M. Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis. J. Fam. Pract., 2002, vol. 51, no. 5, pp. 425–430.
Witte S., Lasek R., Victor N. Wirksamkeit von Ademetionin und Oxaceprol für die Behandlung von Arthrosen Eine Metaanalyse. Orthopade, 2002, vol. 31, pp. 1058–1065.
Ehrenfeld M., Tincani A., Andreoli L., Cattalini M., Greenbaum A., Kanduc D., Alijotas-Reig J., Zinserling V., Semenova N., Amital H., Shoenfeld Y. COVID-19 and autoimmunity. Autoimmun Rev.,2020, vol. 19, no. 8, e102597.
Kottur J., White K. M., Rodriguez M. L., Rechkoblit O., Quintana-Feliciano R., Nayar A., García- Sastre A., Aggarwal A. K. Structures of SARS-CoV-2 N7-methyltransferase with DOT1L and PRMT7 inhibitors provide a platform for new antivirals. PLoS Pathog., 2023, vol. 19, no. 7, e1011546.
Downloads
Published
2024-03-20 — Updated on 2024-04-02
Versions
- 2024-04-02 (2)
- 2024-03-20 (1)
How to Cite
Churilov, L., de Carvalho, J. F. ., Lerner, A. ., Sobolevskaya, P., Basina, A., & Gavrilova , N. . (2024). S-adenosylmethionine therapy in rheumatic and related autoimmune diseases. Vestnik of Saint Petersburg University. Medicine, 18(4), 348–360. https://doi.org/10.21638/10.21638/spbu11.2023.401 (Original work published March 20, 2024)
Issue
Section
Internal medicine
License
Articles of "Vestnik of Saint Petersburg University. Medicine" are open access distributed under the terms of the License Agreement with Saint Petersburg State University, which permits to the authors unrestricted distribution and self-archiving free of charge.
